IFS pédiatrique avec âge néonatal (<3 mois), faible poids à la naissance / manque de prosp...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

ID	`RF-IFS-FRAILTY-AGE`
Type	Signal d’alerte
État	reviewed 2026-04-27 \| pending_clinical_signoff
Maladies	`DIS-IFS`
Sources	`SRC-NCCN-PEDIATRIC-SARCOMA`

Origine du drapeau rouge

Définition	Pediatric IFS with neonatal age (<3 months), low birth weight / failure to thrive (weight <-2SD for age), or hemodynamic instability — VAC cytotoxic protocols poorly tolerated in this very-young population; larotrectinib / entrectinib are the substantially safer alternative. This is the pediatric counterpart of adult frailty-age.
Direction clinique	désescalade
Catégorie	âge de fragilité

Logique de déclenchement

{
  "any_of": [
    {
      "comparator": "<",
      "finding": "age_months",
      "threshold": 3
    },
    {
      "comparator": "<",
      "finding": "weight_for_age_zscore",
      "threshold": -2
    },
    {
      "finding": "hemodynamic_instability",
      "value": true
    }
  ],
  "type": "composite_clinical"
}

Notes

IFS often presents at birth or in the first 6 months of life; very young infants tolerate cytotoxic chemotherapy poorly (myelosuppression, hepatic immaturity, cardiac sensitivity to anthracyclines). VAC protocol carries significant infectious mortality in <3 months. The emergence of TRK-inhibitors (larotrectinib pediatric label down to newborns; entrectinib down to 1 month) has transformed practice — these agents have ORR >90% and are the preferred 1L for fusion-positive IFS in this age group. This frailty flag pushes harder toward TRK- inhibitor monotherapy when fusion-positive (>90% of cases).

Utilisé par

No reverse references found in the YAML corpus.